LLY•benzinga•
Eli Lilly Announced Topline Phase 3 Results From ACHIEVE-1, Evaluating The Safety And Efficacy Of Orforglipron Compared To Placebo In Adults With Type 2 Diabetes And Inadequate Glycemic Control With Diet And Exercise Alone
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on April 17, 2025 by benzinga